




Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



## LETTER TO THE EDITOR

### Myocarditis and COVID-19 mRNA vaccination



### Miocardite e vacina mRNA anti-Covid 19

To the Editor:

We would like to comment on "Acute myocarditis after SARS-CoV-2 vaccination in a 24-year-old man" by Cimaglia et al.<sup>1</sup> They reported an interesting case and concluded that "myocarditis may also occur after administering the vaccine against SARS-CoV-2." Regarding pathomechanisms, Cimaglia et al. discussed the role of autoimmunity.<sup>1</sup> If there is an immunopathological process, an abnormal immunoglobulin profile should be demonstrated. An abnormal immune response might be a cause but there are also other possible causes, one of which is the induction of hyperviscosity by vaccination.<sup>2</sup> A relationship between hyperviscosity and acute myocarditis has been confirmed<sup>3</sup> and hyperviscosity induced by vaccination might also be a cause of myocarditis.<sup>4</sup>

### Conflicts of interest

The authors have no conflicts of interest to declare.

## References

1. Cimaglia P, Tolomeo P, Rapezzi C. Acute myocarditis after SARS-CoV-2 vaccination in a 24-year-old man. Rev Port Cardiol. 2021; S0870-2551(21)00324-3.
2. Joob B, Wiwanitkit V. Expected viscosity after COVID-19 vaccination, hyperviscosity and previous COVID-19. Clin Appl Thromb Hemost. 2021;27, 10760296211020833.
3. Sanchez-Petitto G, Hardy N, Burke A, et al. Eosinophilic myocarditis in a patient with multiple myeloma. Clin Lymphoma Myeloma Leuk. 2020;20:e392–4.
4. Sookaromdee P, Wiwanitkit V. Acute myocardial injury following COVID-19 vaccination. J Prim Care Community Health. 2021;12, <http://dx.doi.org/10.1177/21501327211039986>.

Rujittika Mungmumpuntipantip<sup>a</sup>, Viroj Wiwanitkit<sup>b,\*</sup>

<sup>a</sup>Private Academic Consultant, Bangkok, Thailand

<sup>b</sup>Dr DY Patil University, Pune, India

\* Corresponding author.

E-mail address: [wviroj@yahoo.com](mailto:wviroj@yahoo.com) (V. Wiwanitkit).